Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier
Nicolas Santander, … , Christer Betsholtz, Thomas D. Arnold
Nicolas Santander, … , Christer Betsholtz, Thomas D. Arnold
Published May 5, 2020
Citation Information: J Clin Invest. 2020;130(8):4055-4068. https://doi.org/10.1172/JCI136578.
View: Text | PDF
Research Article Angiogenesis Development

Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier

  • Text
  • PDF
Abstract

Fowler syndrome is a rare autosomal recessive brain vascular disorder caused by mutation in FLVCR2 in humans. The disease occurs during a critical period of brain vascular development, is characterized by glomeruloid vasculopathy and hydrocephalus, and is almost invariably prenatally fatal. Here, we sought to gain insights into the process of brain vascularization and the pathogenesis of Fowler syndrome by inactivating Flvcr2 in mice. We showed that Flvcr2 was necessary for angiogenic sprouting in the brain, but surprisingly dispensable for maintaining the blood-brain barrier. Endothelial cells lacking Flvcr2 had altered expression of angiogenic factors, failed to adopt tip cell properties, and displayed reduced sprouting, leading to vascular malformations similar to those seen in humans with Fowler syndrome. Brain hypovascularization was associated with hypoxia and tissue infarction, ultimately causing hydrocephalus and death of mutant animals. Strikingly, despite severe vascular anomalies and brain tissue infarction, the blood-brain barrier was maintained in Flvcr2 mutant mice. Our Fowler syndrome model therefore defined the pathobiology of this disease and provided new insights into brain angiogenesis by showing uncoupling of vessel morphogenesis and blood-brain barrier formation.

Authors

Nicolas Santander, Carlos O. Lizama, Eman Meky, Gabriel L. McKinsey, Bongnam Jung, Dean Sheppard, Christer Betsholtz, Thomas D. Arnold

×

Figure 1

Flvcr2 inactivation in mice models human PVHH.

Options: View larger image (or click on image) Download as PowerPoint

Flvcr2 inactivation in mice models human PVHH.
(A) Coronal sections thr...
(A) Coronal sections through the lateral ventricles at the indicated embryonic stages were stained to visualize GFP and the endothelial cell marker CD31. Dotted violet lines delineate the ventricles. Boxed areas show magnified areas of the LGE. Numbers indicate the number of embryos with the represented phenotype. Scale bars: 200 μm. (B) Vessels in embryonic brains were stained with CD31 and ERG antibodies. A representative dilated vessel (from 5 E14.5 embryos with the phenotype) in the Flvcr2GFP/GFP GE is shown. L, vessel lumen. Scale bar: 50 μm. (C) Fraction of brain area covered by CD31+ cells. ***P < 0.001, t test. E12.5, n = 4; E14.5, n = 6; E18.5, n = 7–8. (D) Thickness of periventricular vessels. ***P < 0.001, t test. E12.5, n = 4; E14.5, n = 6; E18.5, n = 7–8. (E) Fluorescence intensity profile of CD31 in the LGE of Flvcr2+/GFP and Flvcr2GFP/GFP embryos at E14.5 expressed as mean (solid line) + SEM (shaded area). n = 6. (F) Coronal sections of E14.5 brains were obtained from embryos with constitutive (Flvcr2ΔEC) deletion of Flvcr2 in endothelial cells and stained for GFP and CD31. Scale bars: 200 μm. (G) Coronal sections of E18.5 brains were stained for SOX9 (a marker of apical neuro/glia progenitors at this stage) to reveal the ventricle wall. Scale bar: 500 μm. (H) Ventricle area was compared in mutants and controls. *P < 0.05, t test. Flvcr2+/GFP, n = 8; Flvcr2GFP/GFP, n = 7.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts